{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-099173","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2021-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.413661+00:00","generated_at":"2026-06-29T23:28:06.238077+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kiniksa posts Q2 ARCALYST revenue of $7.7M; net loss $41.6M; guides Q3 rev $9-10M","bullets":["ARCALYST net revenue $7.7M in first quarter of sales (April 1 launch); >100 physicians prescribed in Q2.","Net loss $41.6M vs $37.5M YoY; operating expenses $48.3M (incl $5.7M stock comp).","Cash and investments $225.9M, no debt; expects to fund operations into 2023.","Q3 2021 ARCALYST revenue guidance $9-10M; pipeline: mavrilimumab Ph3 data Q1 2022, KPL-404 Ph2 start Q4 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-099173","json":"https://secwatch.observer/filing/0001104659-21-099173.json","markdown":"https://secwatch.observer/filing/0001104659-21-099173.md","text":"https://secwatch.observer/filing/0001104659-21-099173.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465921099173/0001104659-21-099173-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465921099173/tm2123663d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T23:28:06.238077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}